NewMarket generated $698.5 million in revenue and $111.2 million in net income in Q2 2025. EPS increased slightly despite lower petroleum additives revenue and shipments. Strong performance in specialty materials offset some of the headwinds.

Merit Medical delivered strong Q1 2025 results with revenue and non-GAAP EPS exceeding expectations. Despite a dip in free cash flow, operating margins improved and net income rose.

Merit Medical reported revenue of $355.2 million for Q4 2024, up 9.4% year-over-year, with GAAP EPS of $0.46 and non-GAAP EPS of $0.93. The company achieved strong performance in revenue and profitability, supported by organic growth and acquisitions.

Merit Medical reported better-than-expected financial results in Q3 2024, with revenue increasing by 7.8% to $339.8 million. The company saw improvements in non-GAAP operating margin and non-GAAP EPS, and generated $120 million in free cash flow over the first nine months of 2024. Updated financial guidance for fiscal year 2024 reflects stronger-than-expected organic growth and profitability.

Merit Medical reported a 5.6% increase in revenue to $338.0 million for Q2 2024. The company's GAAP EPS rose by 75.7% to $0.61, while non-GAAP EPS increased by 16.8% to $0.92. Merit Medical also raised its full-year guidance.

Merit Medical reported revenue of $323.5 million for Q1 2024, an 8.7% increase compared to Q1 2023. The company's GAAP EPS increased to $0.48, up 35.5% from $0.36 in the prior year, and non-GAAP EPS increased to $0.77, up 18.7% from $0.64 in the prior year.

Merit Medical Systems, Inc. reported a 10.6% increase in revenue for Q4 2023, reaching $324.5 million. The company's non-GAAP operating margin improved to 18.2%, and it generated approximately $55 million in free cash flow. The company issued fiscal year 2024 guidance, reflecting confidence in continued strong execution, stable growth, improving profitability, and solid free cash flow generation.

Merit Medical reported a 9.8% increase in revenue to $315.2 million for Q3 2023 compared to the same period last year. The company's GAAP operating margin improved to 11.1%, and non-GAAP operating margin increased to 18.3%. GAAP EPS was $0.44, and non-GAAP EPS reached $0.75. The company has raised its fiscal year 2023 financial guidance.

Merit Medical reported an 8.5% increase in revenue to $320.1 million for Q2 2023, with constant currency organic revenue growth of 9.1%. The company also saw improvements in profitability, with non-GAAP gross and operating margins of 51.4% and 19.9%, respectively. GAAP EPS was $0.35 and non-GAAP EPS was $0.81.

Merit Medical reported revenue of $297.6 million for Q1 2023, an 8.0% increase compared to Q1 2022. The company's constant currency revenue, organic, increased by 9.8%. GAAP EPS was $0.36, while non-GAAP EPS was $0.64. The company also delivered significant year-over-year improvements in profitability with non-GAAP gross and operating margins of 50.1% and 16.1%, respectively.

Merit Medical Systems, Inc. reported revenue of $293.4 million for Q4 2022, a 5.4% increase compared to the same period in 2021. The company's GAAP operating margin was 10.4%, and non-GAAP operating margin was 17.8%. GAAP EPS was $0.58, and non-GAAP EPS was $0.79.

Merit Medical Systems, Inc. reported a 7.5% increase in revenue to $287.2 million for the quarter ended September 30, 2022, with a GAAP EPS of $0.27 and a non-GAAP EPS of $0.64. The company's constant currency revenue, organic, increased by 10.5% compared to the prior year period. They are reaffirming their financial targets outlined in the Foundations for Growth Program.

Merit Medical reported revenue of $295.0 million for Q2 2022, a 5.2% increase compared to Q2 2021. The company's constant currency revenue, organic, increased by 7.4%. GAAP EPS was $0.27, and non-GAAP EPS was $0.73. The company delivered better-than-expected revenue and profitability, with a record non-GAAP operating margin of 19.1%.

Merit Medical Systems, Inc. reported revenue of $278.5 million for Q4 2021, a 7.9% increase compared to Q4 2020. GAAP EPS increased 32% year-over-year to $0.36, and non-GAAP EPS increased 31% to $0.71. The company's performance exceeded the high end of its revenue and non-GAAP EPS guidance ranges.

Merit Medical reported a revenue of $267.0 million for Q3 2021, a 9.4% increase compared to Q3 2020. GAAP EPS was $0.21, up from a loss of ($0.05) per share in the prior year, while non-GAAP EPS was $0.52, compared to $0.42 in Q3 2020. The company reaffirmed its full-year revenue and earnings guidance.

Merit Medical reported a strong Q2 2021 with revenue of $280.3 million, a 28.4% increase compared to Q2 2020. GAAP EPS was $0.09, and non-GAAP EPS was $0.62. The company updated its 2021 guidance due to the better-than-expected results and a more favorable outlook for growth in the second half of 2021.

Merit Medical reported a 2.2% increase in revenue to $248.9 million for Q1 2021. The company's GAAP EPS was $0.19, and non-GAAP EPS was $0.52. They also generated $29 million in free cash flow.

Merit Medical Systems, Inc. reported revenue of $258.0 million for the quarter ended December 31, 2020, essentially flat compared to the prior year period. The company's GAAP EPS was $0.27, compared to a GAAP loss per share of ($0.08) in Q4 2019. Non-GAAP EPS was $0.54, compared to $0.40 in Q4 2019.

Merit Medical reported a slight increase in worldwide revenue for Q3 2020, alongside significant growth in non-GAAP operating profit and EPS. The company is focused on enhancing efficiency and is on track with its plan to consolidate facilities and move production lines.

Merit Medical reported a decrease in revenue for Q2 2020, with a worldwide revenue of $218.4 million, a (14.5)% decrease compared to Q2 2019. The company reported a GAAP loss per share of $(0.34) and a non-GAAP EPS of $0.31. Despite the revenue decline, the company generated $32 million in free cash flow and continued progress on strategic goals.

Merit Medical reported a 2.2% increase in worldwide revenue for Q1 2020, reaching $243.5 million. However, the company experienced a GAAP loss per share of $(0.06), compared to a GAAP EPS of $0.11 in Q1 2019. Non-GAAP EPS was $0.38, slightly up from $0.37 in Q1 2019. Due to the uncertainty caused by the COVID-19 pandemic, Merit Medical has withdrawn its FY 2020 guidance.

Merit Medical reported Q4 2019 worldwide revenue of $257.9 million, a 10.6% increase over Q4 2018. The GAAP loss per share was $(0.08), while the non-GAAP EPS was $0.40. The company provided FY 2020 guidance, estimating net sales between $1,044 million and $1,064 million and non-GAAP EPS between $1.58 and $1.68.